In summary, our results have demonstrated that PRC2 is a critical regulator of renal injury in cisplatin‐induced nephropathy and that inhibition of its activity by pharmacological targeting EED can significantly improve renal function and ameliorate renal tubular cell apoptosis and other pathological responses like macrophage infiltration. Here, EED is linked to kidney disorder.